Skip to main content Start of content

HESA Committee Meeting

Notices of Meeting include information about the subject matter to be examined by the committee and date, time and place of the meeting, as well as a list of any witnesses scheduled to appear. The Evidence is the edited and revised transcript of what is said before a committee. The Minutes of Proceedings are the official record of the business conducted by the committee at a sitting.

For an advanced search, use Publication Search tool.

If you have any questions or comments regarding the accessibility of this publication, please contact us at accessible@parl.gc.ca.

Previous day publication Next day publication
MINUTES OF PROCEEDINGS
 
Meeting No. 38
 
Tuesday, April 3, 2012
 

The Standing Committee on Health met at 8:47 a.m. this day, in Room 306, La Promenade Building, the Chair, Joy Smith, presiding.

 

Members of the Committee present: Kelly Block, Patrick Brown, Colin Carrie, Libby Davies, Hon. Hedy Fry, Parm Gill, Wladyslaw Lizon, Dany Morin, Anne Minh-Thu Quach, Djaouida Sellah, Joy Smith and Mark Strahl.

 

Acting Members present: Kellie Leitch for Colin Carrie.

 

In attendance: Library of Parliament: Raphaelle Deraspe, Analyst; Sonya Norris, Analyst.

 

Witnesses: Department of Health: Paul Glover, Assistant Deputy Minister, Health Products and Food Branch; Barbara Sabourin, Director General, Therapeutic Products Directorate, Health Products and Food Branch; Sharon Mullin, Director, Compliance, Enforcement and Coordination Divsion, Health Products and Food Branch. Canadian Pharmacists Association: Jeff Poston, Executive Director; Jeff Morrison, Director, Government Relations and Public Affairs. Canadian Agency for Drugs and Technologies in Health: Brian O'Rourke, President and Chief Executive Officer. As an individual: Joel Lexchin, Professor, School of Health Policy and Management, York University.

 
Pursuant to Standing Order 108(2) and the motion adopted by the Committee on Tuesday, March 13, 2012, the Committee resumed its study of the role of government and industry in determining drug supply in Canada.
 

Libby Davies moved, — That in relation to its study of the role of government and industry in determining drug supply in Canada, the Committee report its findings to the House of Commons.

 

Mark Strahl moved, — That the motion be amended by adding between the words “drug supply in Canada,” and the words “the Committee report its findings to the House of Commons” the following: “how the provinces and territories determine what drugs are required in their jurisdiction, how the industry responds to them, and the impact this has on stakeholders,”.

 

After debate, the question was put on the amendment of Mark Strahl and it was agreed to.

 

The motion, as amended, read as follows:

That in relation to its study of the role of government and industry in determining drug supply in Canada, how the provinces and territories determine what drugs are required in their jurisdiction, how the industry responds to them, and the impact this has on stakeholders, the Committee report its findings to the House of Commons.

 

After debate, the question was put on the motion, as amended, and it was agreed to.

 

Brian O'Rourke, Jeff Poston and Joel Lexchin made statements and, with Jeff Morrison, answered questions.

 

At 9:47 a.m., the sitting was suspended.

At 9:48 a.m., the sitting resumed.

 

Paul Glover made a statement and answered questions.

 

At 10:33 a.m., the sitting was suspended.

At 10:35 a.m., the sitting resumed in camera.

 
The Committee proceeded to the consideration of matters related to Committee business.
 

At 10:47 a.m., the Committee adjourned to the call of the Chair.

 



Mariane Beaudin
Clerk of the Committee

 
 
2012/04/03 2:25 p.m.